CRSP
CRISPR Therapeutics AG
Next earnings Aug 3, 2026 · consensus $-1.23 EPS, $6.69M rev
Last earnings +3.8% on 2026-05-04
$60.08
▲ +6.62%$60.08▲ +26.51%
over 1Y
L $44.34H $76.78
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.6%
1W+11.3%
1M+15.5%
3M+21.3%
YTD+11.7%
1Y+26.5%
Hold
Conviction
Horizon
Long (>12mo)
Street · 32 analysts
Buy
Well-funded clinical-stage gene-editing biotech — minimal revenue and heavy R&D burn, with value resting on pipeline catalysts, not financials.
Revenue $3.51M · FY2025
CRISPR Therapeutics is a gene-editing pioneer whose value is driven by its pipeline and its approved therapy Casgevy (partnered with Vertex), not by its income statement. The financials are those of a clinical-stage biotech: FY2025 revenue was just $3.51M (collaboration revenue is lumpy and fell 90.6%), against an operating loss of -$665M and a net loss of -$582M as the company invests $285M in R&D. The percentage 'margins' (-16,569.8% net) and the 1479.2x P/S are mathematical artifacts of near-zero revenue and carry no analytical meaning here.
What matters for a pre-revenue biotech is the balance sheet and runway, and on that CRISPR is well-positioned. Current assets of $1.99B (cash plus marketable securities) dwarf total liabilities of just $343M, leverage is a negligible 0.18x, and equity is $1.92B. That funds multiple years of the current burn (operating cash flow was -$345M), giving the company time to advance its programs without imminent dilution pressure — though it did issue shares (count +11.9%).
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:57 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $915M | $1.20M | $371M | $37.3M | $3.51M |
| Gross profit | — | — | — | — | — |
| Operating income | $374M | -$673M | -$223M | -$467M | -$665M |
| Net income | $378M | -$650M | -$154M | -$366M | -$582M |
| Diluted EPS | $4.70 | -$8.36 | -$1.94 | -$4.34 | -$6.47 |
| Net margin | 41.3% | -54271.7% | -41.4% | -981.5% | -16569.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$5.57B
EV / EBITDA—
EV / Sales1586.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-9.8%
FCF yield-5.8%
Quality & risk
ROIC (est.)-27.3%
Free cash flow-$346M
Total debt—
Net cash$348M
Altman Z-Score9.14 safe
Piotroski F-Score1/7
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+11.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗4Period ending 2026-06-052026-06-09open ↗S-8Filing2026-06-05open ↗8-KPeriod ending 2026-06-042026-06-04open ↗
Frequently asked
- Is CRISPR Therapeutics AG (CRSP) a buy?
- CRSP currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Well-funded clinical-stage gene-editing biotech — minimal revenue and heavy R&D burn, with value resting on pipeline catalysts, not financials.
- What is CRISPR Therapeutics AG's quality score?
- CRSP scores 35.437537759970766/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001674416, latest 10-Q filed 2026-05-04) · EODHD · Proprietary analysis · as of 6/21/2026, 8:57:19 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.